Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic BW-20829 in Patients with Elevated Lp(a) [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
to developing next-generation siRNA therapies, today announced that the first patient has been dosed in a global Phase 2b clinical trial sponsored by Novartis evaluating DII235, also known as BW-20829, in adults with elevated Lipoprotein (a) (Lp(a)) and Atherosclerotic Cardiovascular Disease (ASCVD). In connection with the molecule's advancement into Phase 2b under its exclusive license and collaboration agreement with Novartis, Argo Biopharma will receive milestone payments that will support ongoing research and development efforts across its hepatic and extra-hepatic siRNA portfolio. BW-20829 is the sixth asset in Argo's pipeline to enter mid-stage global clinical development. "We are pleased that Novartis has advanced BW-20829 into Phase 2b clinical development" said Dr. Dongxu Shu Co-Founder, Chairman of the Board, and Chief Executive Officer of Argo Biopharma. "This milestone underscores the strength of Argo's discovery and early clinical development capabilities, together with
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Even Near an All-Time High, This Dividend ETF Looks Extremely Cheap [Yahoo! Finance]Yahoo! Finance
- Why Analysts Are Closely Watching Novartis AG (NVS) [Yahoo! Finance]Yahoo! Finance
- NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"PR Newswire
- Breakthrough Therapy Status For Ianalumab Could Be A Game Changer For Novartis (SWX:NOVN) [Yahoo! Finance]Yahoo! Finance
- Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25% [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- NVS's page on the SEC website